H.C. Wainwright maintained a positive stance on Esperion Therapeutics (NASDAQ:ESPR) shares, reaffirming a Buy rating and a price target of $16.00. According to InvestingPro data, analyst targets for ...

Bhubaneswar: The buffer zone of Similipal Biosphere Reserve is most affected in forest fires with most incidents linked to ...

Our teaching excellence feeds into a fantastic array of undergraduate degrees in a variety of subjects, while our ground-breaking research has led to: new treatments for ovarian cancer, the discovery ...

Schools around the world have closed to prevent the spread of COVID-19, leaving parents and teachers scrambling to figure out how kids can learn at home. We can help! Science News Explores and the ...

Research studies are often evaluated by other scientists to determine if they are good enough to be published in a journal. Peer reviewers examine the experimental design, methods and statistics ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Crown Research Institutes will be merged as part of sweeping changes to the science sector. In an email to staff seen by RNZ, the seven CRIs will become three mega science organisations - "Public ...

Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) ...

Scientists have found an elusive third form of magnetism that could help solve a longstanding puzzle about superconductors. When you purchase through links on our site, we may earn an affiliate ...